Molecular insights into the α6β4 nicotinic acetylcholine receptor function and ligand recognition

The α6β4 nicotinic acetylcholine receptor (nAChR) is found in the sensory neurons of dorsal root ganglia. It is a promising therapeutic target for pain. However, the difficultly of heterologous functional expression of α6β4 receptor has hindered the discovery of drugs that target it. Here, we functionally express the human α6β4 receptor and determine the cryo-EM structures of α6β4 receptor in complex with its agonists, nicotine and the preclinical drug tebanicline. These structures were captured in non-conducting desensitized states. We elucidate that the stoichiometry of α- and β- subunits in the α6β4 receptor is 2α6:3β4. Furthermore, we identify the binding pockets for nicotine and tebanicline, demonstrating the essential residues contributing to ligand affinity and providing detailed molecular insights into why these agonists have different binding affinities despite both occupying the orthosteric site of the α6β4 receptor. These structures offer significant molecular insight into the function and ligand recognition of α6β4 receptor.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-04-02
DOI
https://doi.org/10.1038/s41467-025-58333-0
Citations
5
Primary Topic
Nicotinic Acetylcholine Receptors Study
Type
article
Field-Weighted Citation Impact
4.03

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Molecular insights into the α6β4 nicotinic acetylcholine receptor function and ligand recognition

Zhuoya Yu, Hongwei Zhang, Yiwei Gao, Zhengji Yin et al.
5 citations
Nature Communications
Nicotinic Acetylcholine Receptors Study
4.03
article

Molecular insights into the α6β4 nicotinic acetylcholine receptor function and ligand recognition

Zhuoya Yu, Hongwei Zhang, Yiwei Gao, Zhengji Yin, Yan Zhao, Jiawei Su, Rilei Yu, Zixuan Zhang, Jun Zhao, Renjie Li, Yufei Meng
article en
5 citations

Abstract

The α6β4 nicotinic acetylcholine receptor (nAChR) is found in the sensory neurons of dorsal root ganglia. It is a promising therapeutic target for pain. However, the difficultly of heterologous functional expression of α6β4 receptor has hindered the discovery of drugs that target it. Here, we functionally express the human α6β4 receptor and determine the cryo-EM structures of α6β4 receptor in complex with its agonists, nicotine and the preclinical drug tebanicline. These structures were captured in non-conducting desensitized states. We elucidate that the stoichiometry of α- and β- subunits in the α6β4 receptor is 2α6:3β4. Furthermore, we identify the binding pockets for nicotine and tebanicline, demonstrating the essential residues contributing to ligand affinity and providing detailed molecular insights into why these agonists have different binding affinities despite both occupying the orthosteric site of the α6β4 receptor. These structures offer significant molecular insight into the function and ligand recognition of α6β4 receptor.

Nature CommunicationsVol. 16(1)
Chinese Academy of Sciences (CN), Institute of Biophysics (CN), Qingdao National Laboratory for Marine Science and Technology (CN), University of Chinese Academy of Sciences (CN), Ocean University of China (CN)
National Natural Science Foundation of China, Chinese Academy of Sciences, National Key Research and Development Program of China, Institute of Biophysics, Chinese Academy of Sciences, National Laboratory of Biomacromolecules
Good health and well-being
Openalex Percentile: Top 7%
Nicotinic Acetylcholine Receptors Study
4.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.